Additionally, makaluvamine analogs (Wang et al., 2019b; Wang et al., 2018; Wang et al., 2009) and SP141 (Cissé et al., 2020; Patil et al., 2017; Punganuru et al., 2020; Wang et al., 2019c; Wang et al., 2014b; Wang et al., 2014c; Wang et al., 2020) have been developed to promote MDM2 degradation, demonstrating strong anti-tumor effects independent of p53 status across multiple cancer types. The gene discussed is MDM2; the disease is neoplasm.